Bracco Diagnostic Imaging
Bracco Imaging specializes in the development and marketing of diagnostic imaging agents for various medical imaging modalities, including X-ray, computed tomography, nuclear medicine, and magnetic resonance imaging (MRI). The company offers a range of products, such as Isovue, an iopamidol injection for X-ray and CT imaging, and ProHance, a gadolinium-based contrast agent for MRI. In nuclear medicine, Bracco provides agents like CardioGen-82 for myocardial perfusion imaging and Choletec for hepatobiliary imaging. Additionally, the company produces gastroenterology-related products and ultrasound contrast agents, enhancing the safety and efficacy of diagnostic procedures. Founded in 1994 and based in Princeton, New Jersey, Bracco Imaging operates as a subsidiary of Bracco S.p.A., focusing on improving patient care through advanced imaging solutions and professional services for healthcare providers.
Blue Earth Diagnostics
Acquisition in 2019
Blue Earth Diagnostics Limited is a molecular imaging diagnostics company focused on developing and commercializing innovative positron emission tomography (PET) imaging agents for cancer management. The company specializes in detecting and localizing prostate cancer, particularly in men experiencing biochemical recurrence, through its flagship product, Axumin. Additionally, Blue Earth is advancing a range of prostate-specific membrane antigen (PSMA)-targeting radiohybrid agents, which are investigational theranostic compounds with potential applications in both imaging and treatment of prostate cancer. The company aims to address significant unmet medical needs in oncology, enhancing the efficiency of diagnosis and treatment for patients with prostate and brain cancers. Founded in 2013 and headquartered in Oxford, United Kingdom, Blue Earth Diagnostics also has offices in Burlington, Massachusetts, and Dublin, Ireland. It operates as a subsidiary of Bracco Imaging S.p.A.
SurgVision
Acquisition in 2017
SurgVision BV is a Netherlands-based company that specializes in developing near-infrared fluorescence molecular imaging technology for clinical applications. Founded in 2011, SurgVision focuses on creating innovative solutions for fluorescence image-guided surgery, utilizing high-definition cameras and molecular probes. The company's Multi-Spectral Normalized Imaging platform enables precise visualization of healthy and cancerous tissues, particularly in breast cancer surgeries, allowing surgeons to effectively distinguish between various tissue types. As of October 2017, SurgVision operates as a subsidiary of Bracco Imaging S.p.A.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.